LETTERS TO THE EDITOR

Diabetic cardiomyopathy: a controversial entity

We read with interest the study by Konduracka et al., 1 which concludes that patients with long-term type 1 diabetes mellitus under intensive insulin treatment do not have echocardiographic, biochemical, or morphological signs of diabetic cardiomyopathy. However, as the authors admit, this is directly opposed to several previous studies which clearly show the presence of myocardial diastolic dysfunction in patients with type 1 diabetes, when compared with control subjects. 2–4 Importantly, like Konduracka et al. 1 diabetes, when compared with control subjects, diastolic dysfunction in patients with type 1 diabetes is much less dependent on loading conditions compared with conventional echocardiography. 5 Since 89% of their cohort had diabetic retinopathy and 45% cardiovascular autonomic neuropathy, the absence of even mild impairment in left ventricular relaxation is very surprising. 6 With such a high incidence of the aforementioned diabetic complications, one would expect increased prevalence of microalbuminuria and diabetic nephropathy, but the authors do not present data on renal function. Moreover, it seems that their cohort did not exhibit ideal glycaemic control over time, and this makes the presence of diabetic cardiomyopathy even more likely. Interestingly, all 17 deceased diabetic patients had, at autopsy, microscopic evidence of small vessel diabetic complications and the majority of them had also cardiac fibrosis. It is therefore surprising that these 17 deceased patients with long-standing diabetes (mean duration >20 years) with evidence of poor glycaemic control (HbA1c 8.4%) and histological evidence of cardiac disease had no abnormality on echocardiography. Another issue that needs further clarification by the authors is whether their diabetic subjects were under any other medications apart from insulin and statins. If the majority of their diabetic population was under treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, as one would expect for the treatment of diabetic retinopathy or other microvascular complications, 7,8 then this may well have influenced the echocardiographic measurements. Furthermore, N-terminal pro-B type natriuretic peptide levels are affected by inhibition of the renin–angiotensin system, 9 and perhaps even the biochemical results should be interpreted with caution.

The study by Konduracka et al. 1 raises major concerns, but we need to admit that any study on diabetic cardiomyopathy poses several difficulties because of the several confounding factors (i.e. hypertension, coronary atherosclerosis, glycaemic control, and medications) that come into play. Finally, we believe that although diabetic cardiomyopathy is a controversial entity, compelling epidemiological and clinical data support its occurrence in humans.

References

Theodoros D. Karamitsos
Department of Cardiovascular Medicine
John Radcliffe Hospital
University of Oxford
Headley Way
Headington
Oxford
Oxfordshire OX3 9DU
UK
Tel: +44 1865 221873
Fax: +44 1865 221111
Email: theo.karamitsos@cardiov.ox.ac.uk

Apostolos Tsapas
Oxford Centre for Diabetes, Endocrinology and Metabolism
Churchill Hospital
Oxford
UK

Jayanth R. Arnold
Department of Cardiovascular Medicine
University of Oxford
John Radcliffe Hospital
Oxford
UK

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org